First Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With Anakinra
- 1 October 2013
- journal article
- case report
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 132 (4), e1043-e1047
- https://doi.org/10.1542/peds.2012-3935
Abstract
YM is the first son of Tunisian consanguineous parents who developed, at 2 weeks of life, an erythematous and scaly eruption, with subsequent rapid evolution toward generalized pustular psoriasis. Afterward, cutaneous flares of diffuse erythematous rash and pustules involving the whole body appeared, with a once weekly periodicity. Intense irritability was present during flares without fever. Moreover, since 1 month of age the infant presented with diarrhea, dysphagia, and reduced feeding rate, with failure to thrive. Laboratory tests during acute flares showed marked leukocytosis, thrombocytosis, and anemia without C-reactive protein elevation. Skin biopsy and clinical presentation were consistent with pustular psoriasis; nevertheless, the patient did not respond to high-potency topical corticosteroids and retinoid acid. As the patient presented with repeated skin flares early after birth, as well as serious constitutional distress with failure to thrive, an autoinflammatory syndrome like interleukine-1-receptor antagonist deficiency or interleukin-36-receptor antagonist deficiency (DITRA) was considered. The hypothesis was reinforced by parental consanguinity, and absence of skin lesion improvement under standard topical treatment. Genetic analyses showed a homozygous mutation in the IL36RN gene (L27P), which represents the same mutation recently described in DITRA patients. At age 6 months we started treatment with the recombinant interleukin-1 receptor antagonist anakinra with efficacy both on constitutional symptoms and skin involvement. DITRA is a recently described autoinflammatory disease characterized by repeated flares of generalized pustular psoriasis, high fever, asthenia, and systemic inflammation. We report herein the first exhaustive clinical description of an infant with DITRA who was successfully treated with anakinra.This publication has 9 references indexed in Scilit:
- Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular PsoriasisAmerican Journal of Human Genetics, 2011
- Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular PsoriasisThe New England Journal of Medicine, 2011
- Efficacy of Anti-Interleukin-1 Receptor Antagonist Anakinra (Kineret®) in a Case of Refractory Sweet’s SyndromeDermatology, 2011
- Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN MutationsAnnals of Internal Medicine, 2010
- An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)Clinical Rheumatology, 2010
- Anakinra for Difficult-to-Treat Neutrophilic Panniculitis: IL-1 Blockade as a Promising Treatment Option for Neutrophil-Mediated Inflammatory Skin DiseaseDermatology, 2010
- An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor AntagonistThe New England Journal of Medicine, 2009
- An Autoinflammatory Disease Due to Homozygous Deletion of theIL1RNLocusThe New England Journal of Medicine, 2009
- Identification and Initial Characterization of Four Novel Members of the Interleukin-1 FamilyJournal of Biological Chemistry, 2000